Ranbaxy Laboratories announced that it has received approval from the Food and Drug Administration (FDA) for manufacturing and marketing of Fenofibrate Capsules, the generic equivalent of Lupin’s Antara.

Antara is a fibrate indicated as an adjunct to diet when response to nondrug therapy is inadequate in hypertriglyceridemia (Types IV and V), to reduce elevated total-C, LDL-C, apo B, and TG, and to increase HDL-C, in primary hypercholesterolemia and mixed dyslipidemia (Type IIa and IIb).

RELATED: Dyslipidemia Drug Indications

Fenofibrate Capsules will be available in 43mg and 130mg strengths.


Continue Reading

For more information call (800) 406-7984 or visit Ranbaxy.com.